4.1 Review

The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature

Journal

CURRENT OPINION IN PULMONARY MEDICINE
Volume 17, Issue -, Pages S35-S41

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.mcp.0000410746.82840.79

Keywords

chronic obstructive pulmonary disease; direct costs; elderly; exacerbations

Funding

  1. Fondazione Charta
  2. Bayer Italy
  3. Pfizer Italy
  4. Celgene International
  5. Medidata
  6. Bristol-Myers Squibb
  7. Nycomed
  8. Boehringer Ingelheim
  9. Merck Serono
  10. Novartis
  11. Pfizer
  12. Otsuka
  13. Janssen
  14. Air Liquide
  15. Stallergenes
  16. Almirall
  17. Vifor
  18. Viropharma

Ask authors/readers for more resources

Purpose of review Chronic obstructive pulmonary disease (COPD) is a high prevalence condition with a significant clinical and economic burden. In elderly people, COPD is often associated with other chronic comorbidities (i.e. cardiovascular diseases), determining clinical complications and requiring frequent acute healthcare interventions. The aim of this article is to review the economic studies evaluating costs and healthcare resource utilization in elderly (>= 65 years) COPD patients. Recent findings Sixteen of the initial 359 articles retrieved through our research strategy were found to include relevant cost information on elderly COPD patients or to evaluate the effect of older age on healthcare expenditure. Most studies were carried out in the United States and used administrative database claims to determine resource consumption and direct costs (attributable and not). Very few studies focused exclusively on elderly patients. Summary Results showed a certain variability of cost estimations, mainly due to the different methodologies and adopted cost approach. However, we found a trend of direct cost growth in the elderly population, which can be explained by a more frequent use of acute healthcare services, especially for managing COPD exacerbations. These results cannot be considered definitive and new studies, targeting elderly people, are required in order to confirm these preliminary findings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available